Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2007

View Archived Issues

Aripiprazole improves psychotic symptoms in Alzheimer's dementia patients

Gabapentin ineffective in tinnitus studies

Pramipexole to be evaluated for Tourette's syndrome / News in Context

BioAlliance updates clinical development for Loramyc and acyclovir Lauriad

DOR BioPharma enters named patient access program with Orphan Australia for orBec

Cytos initiates two phase II studies of Immunodrug CYT003-QbG10 in allergy indications

Oasmia enters license and distribution agreement with Orion for Paclical

In vitro results suggest potential benefit of ICA-27243 as an anticonvulsant

New therapeutic agents for metabolic disorders imparted in recent patents

Recent patents describe novel psychopharmacological agents

Novel therapeutic agents for cardiovascular disorders reported in recent patent literature

Symptomatic and asymptomatic QTc prolongation observed in phase I trial of ARQ-171

FDA grants AstraZeneca six months pediatric exclusivity patent extension for Arimidex

GSK stands by Serevent and Advair following meeting with FDA

Amarin initiates phase I clinical trial of treatment for niacin-induced flushing

Sucampo Pharma initiates phase IIb study of lubiprostone in Japan

European Commission grants orphan medicinal product designation to Revlimid

First patient completes StemCells' phase I clinical trial of HuCNS-SC

Sanofi-aventis and Astellas restructure Japanese joint venture Fujisawa sanofi-aventis

Bavarian Nordic reports positive results from phase II trial of Imvamune smallpox vaccine

Forest Laboratories reports positive results from phase III study of Lexapro

Lundbeck reports third quarter 2007 results

A potential role for CLCN2 in absence epilepsy

GABA-A alpha1 subunit misfolding caused by mutations associated with juvenile myoclonic epilepsy

Pediatric hypertension indication for Novartis' Diovan receives FDA approval

Health Canada approves Merck Frosst's Isentress for HIV-1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...